2024
Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopauseThe Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatment
2023
Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data
Lantis K, Schnell P, Bland C, Wilder J, Hock K, Vargo C, Glover N, Hackney M, Lustberg M, Worthen-Chaudhari L. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data. Trials 2023, 24: 564. PMID: 37658464, PMCID: PMC10472642, DOI: 10.1186/s13063-023-07554-z.Peer-Reviewed Original ResearchConceptsChemotherapy-induced neuropathyPhysical activityBackgroundBreast cancerOutcome measuresNon-pharmacologic interventionsBreast cancer survivorsPrimary outcome measureHome exercise interventionQuality of lifeControl intervention groupPreliminary baseline dataPrimary endpointExercise interventionBC survivorsTertiary outcomesCancer survivorsSensorimotor symptomsClinical trialsIntervention groupTwo-armWeek 8Mean changeFall riskPrimary estimandTreatment groupsFemale reproductive health in pediatric, adolescent, and young adult cancer survivors
Hoefgen H, Benoit J, Chan S, Jayasinghe Y, Lustberg M, Pohl V, Saraf A, Schmidt D, Appiah L. Female reproductive health in pediatric, adolescent, and young adult cancer survivors. Pediatric Blood & Cancer 2023, 70: e29170. PMID: 37381166, DOI: 10.1002/pbc.29170.Peer-Reviewed Original ResearchConceptsQuality of lifeGenital graftHost diseaseCancer survivorsLate effectsReproductive healthHematopoietic stem cell transplantCancer treatmentYoung adult cancer survivorsHormone replacement therapyCervical cancer screeningStem cell transplantFemale reproductive healthAdult cancer survivorsLarge cohort studyLikelihood of pregnancyYoung Adult Cancer SurvivorshipAdult cancer survivorshipGynecologic outcomesVaginal injuryCohort studyCell transplantReplacement therapyCancer careCancer screeningMitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Lustberg M, Kuderer N, Desai A, Bergerot C, Lyman G. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology 2023, 20: 527-542. PMID: 37231127, PMCID: PMC10211308, DOI: 10.1038/s41571-023-00776-9.Peer-Reviewed Original ResearchConceptsAdverse eventsEvidence-based clinical practice guidelinesChemotherapy-associated adverse eventsNon-pharmacological treatment strategiesAdverse effectsClinical practice guidelinesAdverse treatment effectsCourse of therapyTotality of evidenceQuality of lifeTerms of survivalRisk assessment toolOptimal therapyCancer survivorsRisk factorsOncology practiceTreatment strategiesPractice guidelinesUnderlying biological mechanismsAppropriate managementAnticancer treatmentCancer treatmentEffective interventionsTreatment effectsChemotherapyDesign and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity
Haynam M, Chaplow Z, DeScenza V, Bowman J, Dispennette K, Zhang X, Kilar M, Hohn S, Fairman C, Lustberg M, Focht B. Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity. Contemporary Clinical Trials Communications 2023, 33: 101154. PMID: 37250507, PMCID: PMC10220259, DOI: 10.1016/j.conctc.2023.101154.Peer-Reviewed Original ResearchBreast cancer survivorsLifestyle weight management interventionsWeight management programWeight management interventionsPilot trialCancer survivorsPreliminary efficacyPilot intervention trialPatient-reported outcomesLifestyle behavior changeSignificant weight gainBreast cancer treatmentMode of deliveryCommunity-based intervention modelMulti-component interventionCommunity-based interventionsQuality of lifeTrial feasibilityDietary modificationCardiometabolic diseasesIntervention trialsCancer recurrenceEfficacy trialsOverweightWeight gainFramework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)
Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care In Cancer 2023, 31: 293. PMID: 37086308, DOI: 10.1007/s00520-023-07734-2.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neurotoxicityPhysical therapy guidelinesPhysical therapistsPhysical therapyCIPN assessmentPeripheral neurotoxicityOncology teamTherapy guidelinesHome-based exercise prescriptionBurden of chemotherapyManual therapy interventionsClinical practice guidelinesPhysical therapy assessmentLimited effective treatmentsQuality of lifePhysical performance measuresSymptom management researchCIPN treatmentNeurologic symptomsMotor dysfunctionPatient functionExercise prescriptionAerobic trainingChemotherapy agentsPractice guidelinesRetrospective cohort study of scalp cooling in breast cancer patients
Rose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.Peer-Reviewed Original ResearchConceptsScalp coolingChemotherapy regimenPatient ageInsurance statusRetrospective cohort studyCommon side effectsRetrospective chart reviewNon-white patientsBreast cancer patientsStage of cancerQuality of lifeChart reviewCohort studyWhite patientsPatient's likelihoodChemotherapy infusionCancer patientsTreatment optionsOncology settingBreast cancerPatient decisionSide effectsPatientsTreatment planHealthcare providers
2022
Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
Williams N, Grimm M, Gast K, Lustberg M. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Current Breast Cancer Reports 2022, 14: 142-152. DOI: 10.1007/s12609-022-00463-1.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerSystemic therapyClinical outcomesER-positive breast cancerTriple-negative breast cancerBreast cancer supportRobust clinical outcomesOptimized clinical outcomesQuality of lifePersonalized medicine approachNeoadjuvant regimensAdditional therapyEndocrine therapySelect patientsClinical trialsBest therapyPrognostic biomarkerPatientsCancer supportTherapyMedicine approachCancerRoutine useGenomic testing
2021
Supportive Care: Low Cost, High Value.
Popescu RA, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. American Society Of Clinical Oncology Educational Book 2021, 41: 1-11. PMID: 33830830, DOI: 10.1200/edbk_320041.Peer-Reviewed Original ResearchConceptsQuality of lifePhysical exerciseChemotherapy-induced peripheral neuropathyLarge phase III trialsElectronic patient-reported outcome measuresPatient-reported outcome measuresPersonalization of chemotherapySupportive care unitPhase III trialsSupportive care interventionsCancer-related fatigueMind-body interventionsNonpharmacologic strategiesScrambler therapyGastrointestinal dysmotilityIII trialsOverall survivalSupportive careTreatable causeMuscle trainingPeripheral neuropathyCare unitClinic appointmentsMetabolic derangementsRegular screeningA Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study
Zvinovski F, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Mehta L, Foraker R, Gulati M, Lustberg M, Quick AM. A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study. Journal Of Oncology 2021, 2021: 9965583. PMID: 34135964, PMCID: PMC8178006, DOI: 10.1155/2021/9965583.Peer-Reviewed Original ResearchBreast cancer survivorsSerious adverse eventsBrief Fatigue InventoryCancer survivorsQLQ-C30Risk factorsStudy protocolSingle-arm feasibility studyCardiovascular disease risk factorsVO2 maxCVD risk factorsCardiac rehabilitation programDisease risk factorsCardiac rehabilitation interventionsBreast cancer populationQuality of lifeSecondary endpointsAdverse eventsCR programPreliminary efficacyCancer patientsCancer populationFatigue InventoryOverall adherenceMean changeEmerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers 2021, 13: 766. PMID: 33673136, PMCID: PMC7918689, DOI: 10.3390/cancers13040766.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPeripheral neuropathyPathogenesis of CIPNTreatment of CIPNFirst-line chemotherapeutic agentNon-pharmacological therapeuticsCommon adverse eventsNon-pharmacological strategiesQuality of lifeAdverse eventsClinical outcomesCancer survivorsEffective intervention strategiesClinical trialsSide effectsChemotherapeutic agentsEffective interventionsVinca alkaloidsNew targetsIntervention strategiesNeuropathyPrior failureClinical researchersPlatinum compoundsTherapeutics
2020
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group
Mayo SJ, Lustberg M, M. Dhillon H, Nakamura ZM, Allen DH, Von Ah D, C. Janelsins M, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D’Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Supportive Care In Cancer 2020, 29: 2821-2840. PMID: 33231809, DOI: 10.1007/s00520-020-05860-9.Peer-Reviewed Original ResearchConceptsCancer-related cognitive impairmentNon-central nervous system cancersNervous system cancersOncology providersSystem cancersNon-central nervous system malignanciesCognitive impairmentNervous system malignanciesQuality of lifeOncology cliniciansStudy groupFunctional abilityPatientsCancerImpairmentContext of adultProvidersMalignancyCliniciansDiseaseCaregiversPsychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Lockwood B, El-Jawahri A, Walker A, Russell D, Gustin J, Ehrman S, Bose-Brill S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-140589.Peer-Reviewed Original ResearchPatient-reported outcomesAcute myeloid leukemiaHigh-risk acute myeloid leukemiaQuality of lifeEdmonton Symptom Assessment SystemInduction chemotherapyWeek 2Older adultsYoung adultsPTSD symptomsPC interventionsSymptom burdenPsychological distressSignificant lower QOLRefractory acute myeloid leukemiaAdvisory CommitteeLower QOLCancer Therapy-LeukemiaIntensive induction chemotherapySignificant higher anxietyStandard oncology careInitiation of chemotherapyPalliative care interventionsPsychological symptom burdenChance of cureWorry and rumination in breast cancer patients: perseveration worsens self-rated health
Renna ME, Rosie Shrout M, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Malarkey WB, Kiecolt-Glaser JK. Worry and rumination in breast cancer patients: perseveration worsens self-rated health. Journal Of Behavioral Medicine 2020, 44: 253-259. PMID: 33135103, PMCID: PMC8272958, DOI: 10.1007/s10865-020-00192-9.Peer-Reviewed Original ResearchConceptsSelf-rated healthBreast cancer patientsBreast Cancer Prevention Trial Symptom ChecklistCancer-related distressBreast cancer symptomsPoor physical functioningPhysical functioningCancer patientsPhysical symptomsAdjuvant treatmentCancer symptomsGreater cancer-related distressHigher cancer-related distressGreater painLower self-rated healthBody mass indexQuality of lifePhysical comorbiditiesMass indexRAND-36Menopause statusCancer stageCancer trajectorySymptom ChecklistSymptomsPROMIS-10 scores at six months post-baseline among breast and gynecologic oncology patients participating in a text-based symptom monitoring program with patient navigation.
Naughton M, Salani R, Lustberg M, Peng J, Moon J, Loyan H, Paskett E. PROMIS-10 scores at six months post-baseline among breast and gynecologic oncology patients participating in a text-based symptom monitoring program with patient navigation. Journal Of Clinical Oncology 2020, 38: e19173-e19173. DOI: 10.1200/jco.2020.38.15_suppl.e19173.Peer-Reviewed Original ResearchGynecologic oncology patientsPhysical health scoresMental health functioningOncology patientsSymptom SurveyHealth scoresHealth functioningPROMIS-10Higher ageMental health subscale scoresWorse mental health functioningMental healthBaseline PROMIS scoresLower mental health functioningQuality of lifeInterim resultsLower mental healthPoor patient careOnly significant predictorPatient navigationPatient navigatorsPROMIS scoresSymptom managementCancer stagePatient responseA phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.
Noonan A, Lustberg M, Schnell P, Hays J, Jin N, Abushahin L, Malalur P, Roychowdhury S, Elkhatib R, Chen H, Al Mutar S, Sparreboom A, Hu S. A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab. Journal Of Clinical Oncology 2020, 38: tps12125-tps12125. DOI: 10.1200/jco.2020.38.15_suppl.tps12125.Peer-Reviewed Original ResearchOxaliplatin-induced peripheral neuropathyOxaliplatin-induced neuropathyOrganic cation transporter 2Peripheral neuropathyColorectal cancerChronic oxaliplatin-induced peripheral neuropathyStage IV colorectal cancerRat dorsal root gangliaOxaliplatin-induced neurotoxicityPharmacokinetics of oxaliplatinPhase 2 doseMetastatic colorectal cancerPhase 1b trialDose-finding studyDorsal root gangliaAddition of dasatinibQuality of lifeSmall molecule kinase inhibitorsFOLFOX chemotherapyOral dasatinibBevacizumab therapyRoot gangliaSerum biomarkersIntermittent doseRat modelA phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Adams E, Lustberg M, Jin Y, Li Y, Sparreboom A, Hu S. A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer. Journal Of Clinical Oncology 2020, 38: tps12128-tps12128. DOI: 10.1200/jco.2020.38.15_suppl.tps12128.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel infusionFree survivalPeripheral neuropathyBreast cancerPaclitaxel-induced peripheral neuropathyBreast cancer stage IEarly-stage breast cancerGrade 2 neuropathyPhase Ib studyPhase II doseDisease-free survivalCancer stage IStage breast cancerBreast cancer therapyTyrosine kinase inhibitorsQuality of lifeOrganic anion transportingOATP1B1 inhibitionOral nilotinibWeekly paclitaxelPaclitaxel dosePaclitaxel therapyOverall survivalWeekly doses
2019
Palliative care referral patterns of adolescent and young adult patients at a comprehensive cancer center.
Lockwood B, Ntukidem O, Ehrman S, Lustberg M, Bhatnagar B, Klemanski D. Palliative care referral patterns of adolescent and young adult patients at a comprehensive cancer center. Journal Of Clinical Oncology 2019, 37: 63-63. DOI: 10.1200/jco.2019.37.31_suppl.63.Peer-Reviewed Original ResearchAYA populationPalliative careComprehensive cancer centerReferral patternsPC referralAYA patientsCancer CenterOncology careCancer diagnosisComprehensive oncology careIntegrative palliative carePost-discharge followRetrospective chart reviewYoung adult patientsAdvance care planningAdvanced cancer diagnosisQuality of lifeNational Cancer InstituteAYA cancerInpatient referralsPalliative servicesAdult patientsChart reviewPC clinicsOncologic treatment
2018
Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based Chemotherapy
Orchard T, Gaudier-Diaz M, Phuwamongkolwiwat-Chu P, Andridge R, Lustberg M, Bomser J, Cole R, Belury M, DeVries A. Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based Chemotherapy. Nutrients 2018, 10: 2004. PMID: 30567351, PMCID: PMC6316589, DOI: 10.3390/nu10122004.Peer-Reviewed Original ResearchConceptsDHA dietSynaptic damageSecond injectionPro-inflammatory cytokines IL-1βChemotherapy-treated miceKC/GROCytokines IL-1βLong-term brainLow-sucrose dietTwo-injection regimenQuality of lifeSpecific brain regionsBrain DHARegion-specific effectsC57BL/6 miceCancer survivorsFunction markersIL-1βIL-6Synaptic markersIL-5Mouse modelNeuroinflammationSucrose dietChemotherapy